| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
BridgeBio Pharma, Inc.
13G
BBIO · 10806X102
|
5.2% |
5/29/2026
Event 5/22/2026
|
|||
| Farallon Capital Partners, L.P. | 0.4% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.1% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.1% | ||||
| Farallon Healthcare Partners Master, L.P. | 3.0% | ||||
| Farallon Partners, L.L.C. | 5.1% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.1% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 3.0% | ||||
| Dapice Joshua J. | 5.2% | ||||
| Dreyfuss, Philip D. | 5.2% | ||||
| Dunn Hannah E. | 5.2% | ||||
| Gehani, Varun N. | 5.2% | ||||
| Giauque, Nicolas | 5.2% | ||||
| Husen, Avner A. | 5.2% | ||||
| Kim, David T. | 5.2% | ||||
| Linn, Michael G. | 5.2% | ||||
| Luo Patrick (Cheng) | 5.2% | ||||
| Roberts, Jr., Thomas G. | 5.2% | ||||
| Saito Edric C. | 5.2% | ||||
| Short Daniel S. | 5.2% | ||||
| Spokes, Andrew J. M. | 5.2% | ||||
| Warren, John R. | 5.2% | ||||
| Wehrly, Mark C. | 5.2% | ||||
|
InflaRx N.V.
13G
IFRX · N44821101
|
5.1% |
5/14/2026
Event 5/7/2026
|
|||
| Farallon Capital Partners, L.P. | 0.8% | ||||
| Farallon Capital Institutional Partners, L.P. | 1.3% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.1% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.2% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.2% | ||||
| Farallon Capital Offshore Investors II, L.P. | 2.3% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.1% | ||||
| Farallon Partners, L.L.C. | 5.0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.2% | ||||
| Farallon F5 (GP), L.L.C. | 0.1% | ||||
| Dapice Joshua J. | 5.1% | ||||
| Dreyfuss, Philip D. | 5.1% | ||||
| Dunn Hannah E. | 5.1% | ||||
| Gehani, Varun N. | 5.1% | ||||
| Giauque, Nicolas | 5.1% | ||||
| Husen, Avner A. | 5.1% | ||||
| Kim, David T. | 5.1% | ||||
| Linn, Michael G. | 5.1% | ||||
| Luo Patrick (Cheng) | 5.1% | ||||
| Roberts, Jr., Thomas G. | 5.1% | ||||
| Saito Edric C. | 5.1% | ||||
| Short Daniel S. | 5.1% | ||||
| Spokes, Andrew J. M. | 5.1% | ||||
| Warren, John R. | 5.1% | ||||
| Wehrly, Mark C. | 5.1% | ||||
|
Tyra Biosciences, Inc.
13G/A
Amendment 1
TYRA · 90240B106
|
6.6% |
5/12/2026
Event 3/31/2026
|
|||
| Farallon Capital Partners, L.P. | 1.1% | ||||
| Farallon Capital Institutional Partners, L.P. | 1.4% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.2% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.2% | ||||
| Farallon Capital Offshore Investors II, L.P. | 2.7% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.3% | ||||
| Farallon Healthcare Partners Master, L.P. | 0.4% | ||||
| Farallon Partners, L.L.C. | 6.3% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.2% | ||||
| Farallon F5 (GP), L.L.C. | 0.3% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 0.4% | ||||
| Dapice Joshua J. | 6.6% | ||||
| Dreyfuss, Philip D. | 6.6% | ||||
| Dunn Hannah E. | 6.6% | ||||
| Gehani, Varun N. | 6.6% | ||||
| Giauque, Nicolas | 6.6% | ||||
| Husen, Avner A. | 6.6% | ||||
| Kim, David T. | 6.6% | ||||
| Linn, Michael G. | 6.6% | ||||
| Luo Patrick (Cheng) | 6.6% | ||||
| Roberts, Jr., Thomas G. | 6.6% | ||||
| Saito Edric C. | 6.6% | ||||
| Short Daniel S. | 6.6% | ||||
| Spokes, Andrew J. M. | 6.6% | ||||
| Warren, John R. | 6.6% | ||||
| Wehrly, Mark C. | 6.6% | ||||
|
Beta Bionics, Inc.
13G/A
Amendment 4
BBNX · 08659B102
|
8.1% |
5/12/2026
Event 3/31/2026
|
|||
| Zone Healthcare Holdings, LLC | 5.8% | ||||
| Farallon Capital Partners, L.P. | 0.4% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.4% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.1% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.1% | ||||
| Farallon Capital Management, L.L.C. | 5.8% | ||||
| Farallon Partners, L.L.C. | 2.3% | ||||
| Farallon F5 (GP), L.L.C. | 0.1% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Dapice Joshua J. | 8.1% | ||||
| Dreyfuss, Philip D. | 8.1% | ||||
| Dunn Hannah E. | 8.1% | ||||
| Gehani, Varun N. | 8.1% | ||||
| Giauque, Nicolas | 8.1% | ||||
| Husen, Avner A. | 8.1% | ||||
| Kim, David T. | 8.1% | ||||
| Linn, Michael G. | 8.1% | ||||
| Luo Patrick (Cheng) | 8.1% | ||||
| Roberts, Jr., Thomas G. | 8.1% | ||||
| Saito Edric C. | 8.1% | ||||
| Short Daniel S. | 8.1% | ||||
| Spokes, Andrew J. M. | 8.1% | ||||
| Warren, John R. | 8.1% | ||||
| Wehrly, Mark C. | 8.1% | ||||
|
GRAIL, Inc.
13G/A
Amendment 2
GRAL · 384747101
|
7.8% |
5/11/2026
Event 3/31/2026
|
|||
| Farallon Capital Partners, L.P. | 0.6% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.7% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.5% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.2% | ||||
| Farallon Healthcare Partners Master, L.P. | 4.5% | ||||
| Farallon Partners, L.L.C. | 7.7% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.2% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 4.5% | ||||
| Dapice Joshua J. | 7.8% | ||||
| Dreyfuss, Philip D. | 7.8% | ||||
| Dunn Hannah E. | 7.8% | ||||
| Gehani, Varun N. | 7.8% | ||||
| Giauque, Nicolas | 7.8% | ||||
| Husen, Avner A. | 7.8% | ||||
| Kim, David T. | 7.8% | ||||
| Linn, Michael G. | 7.8% | ||||
| Luo Patrick (Cheng) | 7.8% | ||||
| Roberts, Jr., Thomas G. | 7.8% | ||||
| Saito Edric C. | 7.8% | ||||
| Short Daniel S. | 7.8% | ||||
| Spokes, Andrew J. M. | 7.8% | ||||
| Warren, John R. | 7.8% | ||||
| Wehrly, Mark C. | 7.8% | ||||
|
Tango Therapeutics, Inc.
13G/A
Amendment 4
TNGX · 87583X109
|
7.8% |
5/11/2026
Event 3/31/2026
|
|||
| Farallon Capital Partners, L.P. | 0.7% | ||||
| Farallon Capital Institutional Partners, L.P. | 1.0% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.2% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.2% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.7% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.2% | ||||
| Farallon Healthcare Partners Master, L.P. | 3.5% | ||||
| Farallon Partners, L.L.C. | 7.6% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.2% | ||||
| Farallon F5 (GP), L.L.C. | 0.2% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 3.5% | ||||
| Dapice Joshua J. | 7.8% | ||||
| Dreyfuss, Philip D. | 7.8% | ||||
| Dunn Hannah E. | 7.8% | ||||
| Gehani, Varun N. | 7.8% | ||||
| Giauque, Nicolas | 7.8% | ||||
| Husen, Avner A. | 7.8% | ||||
| Kim, David T. | 7.8% | ||||
| Linn, Michael G. | 7.8% | ||||
| Luo Patrick (Cheng) | 7.8% | ||||
| Roberts, Jr., Thomas G. | 7.8% | ||||
| Saito Edric C. | 7.8% | ||||
| Short Daniel S. | 7.8% | ||||
| Spokes, Andrew J. M. | 7.8% | ||||
| Warren, John R. | 7.8% | ||||
| Wehrly, Mark C. | 7.8% | ||||
|
Tyra Biosciences, Inc.
13G
TYRA · 90240B106
|
5.6% |
2/20/2026
Event 2/12/2026
|
|||
| Farallon Capital Partners, L.P. | 0.9% | ||||
| Farallon Capital Institutional Partners, L.P. | 1.2% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.2% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.2% | ||||
| Farallon Capital Offshore Investors II, L.P. | 2.4% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.3% | ||||
| Farallon Partners, L.L.C. | 5.3% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.2% | ||||
| Farallon F5 (GP), L.L.C. | 0.3% | ||||
| Dapice Joshua J. | 5.6% | ||||
| Dreyfuss, Philip D. | 5.6% | ||||
| Dunn Hannah E. | 5.6% | ||||
| Gehani, Varun N. | 5.6% | ||||
| Giauque, Nicolas | 5.6% | ||||
| Husen, Avner A. | 5.6% | ||||
| Kim, David T. | 5.6% | ||||
| Linn, Michael G. | 5.6% | ||||
| Luo Patrick (Cheng) | 5.6% | ||||
| Roberts, Jr., Thomas G. | 5.6% | ||||
| Saito Edric C. | 5.6% | ||||
| Short Daniel S. | 5.6% | ||||
| Spokes, Andrew J. M. | 5.6% | ||||
| Warren, John R. | 5.6% | ||||
| Wehrly, Mark C. | 5.6% | ||||
|
Liquidia Corporation
13G/A
Amendment 2
LQDA · 53635D202
|
9.9% |
2/9/2026
Event 12/31/2025
|
|||
| Farallon Capital Partners, L.P. | 0.8% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.7% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.3% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.2% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.2% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.8% | ||||
| Farallon Capital F5 Master I, L.P. | 0.2% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Healthcare Partners Master, L.P. | 5.7% | ||||
| Farallon Partners, L.L.C. | 9.7% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.2% | ||||
| Farallon F5 (GP), L.L.C. | 0.2% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 5.7% | ||||
| Dapice Joshua J. | 9.9% | ||||
| Dreyfuss, Philip D. | 9.9% | ||||
| Dunn Hannah E. | 9.9% | ||||
| Fried, Richard B | 0% | ||||
| Gehani, Varun N. | 9.9% | ||||
| Giauque, Nicolas | 9.9% | ||||
| Husen, Avner A. | 9.9% | ||||
| Kim, David T. | 9.9% | ||||
| Linn, Michael G. | 9.9% | ||||
| Luo Patrick (Cheng) | 9.9% | ||||
| Patel, Rajiv A. | 0% | ||||
| Roberts, Jr., Thomas G. | 9.9% | ||||
| Saito Edric C. | 9.9% | ||||
| Seybold, William | 0% | ||||
| Short Daniel S. | 9.9% | ||||
| Spokes, Andrew J. M. | 9.9% | ||||
| Warren, John R. | 9.9% | ||||
| Wehrly, Mark C. | 9.9% | ||||
|
Agios Pharmaceuticals, Inc.
13G/A
Amendment 4
AGIO · 00847X104
|
8.8% |
2/9/2026
Event 12/31/2025
|
|||
| Farallon Capital Partners, L.P. | 0.7% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.8% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.2% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.6% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.2% | ||||
| Farallon Healthcare Partners Master, L.P. | 5.0% | ||||
| Farallon Partners, L.L.C. | 8.7% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.2% | ||||
| Farallon F5 (GP), L.L.C. | 0.2% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 5.0% | ||||
| Dapice Joshua J. | 8.8% | ||||
| Dreyfuss, Philip D. | 8.8% | ||||
| Dunn Hannah E. | 8.8% | ||||
| Fried, Richard B | 0% | ||||
| Gehani, Varun N. | 8.8% | ||||
| Giauque, Nicolas | 8.8% | ||||
| Husen, Avner A. | 8.8% | ||||
| Kim, David T. | 8.8% | ||||
| Linn, Michael G. | 8.8% | ||||
| Luo Patrick (Cheng) | 8.8% | ||||
| Patel, Rajiv A. | 0% | ||||
| Roberts, Jr., Thomas G. | 8.8% | ||||
| Saito Edric C. | 8.8% | ||||
| Seybold, William | 0% | ||||
| Short Daniel S. | 8.8% | ||||
| Spokes, Andrew J. M. | 8.8% | ||||
| Warren, John R. | 8.8% | ||||
| Wehrly, Mark C. | 8.8% | ||||
|
Revolution Medicines, Inc.
13G/A
Amendment 3
RVMD · 76155X100
|
7.5% |
2/9/2026
Event 12/31/2025
|
|||
| Farallon Capital Partners, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.7% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.3% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.2% | ||||
| Farallon Healthcare Partners Master, L.P. | 4.4% | ||||
| Farallon Partners, L.L.C. | 7.4% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.2% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 4.4% | ||||
| Dapice Joshua J. | 7.5% | ||||
| Dreyfuss, Philip D. | 7.5% | ||||
| Dunn Hannah E. | 7.5% | ||||
| Fried, Richard B | 0% | ||||
| Gehani, Varun N. | 7.5% | ||||
| Giauque, Nicolas | 7.5% | ||||
| Husen, Avner A. | 7.5% | ||||
| Kim, David T. | 7.5% | ||||
| Linn, Michael G. | 7.5% | ||||
| Luo Patrick (Cheng) | 7.5% | ||||
| Patel, Rajiv A. | 0% | ||||
| Roberts, Jr., Thomas G. | 7.5% | ||||
| Saito Edric C. | 7.5% | ||||
| Seybold, William | 0% | ||||
| Short Daniel S. | 7.5% | ||||
| Spokes, Andrew J. M. | 7.5% | ||||
| Warren, John R. | 7.5% | ||||
| Wehrly, Mark C. | 7.5% | ||||
|
Beta Bionics, Inc.
13G/A
Amendment 3
BBNX · 08659B102
|
9.9% |
2/9/2026
Event 12/31/2025
|
|||
| Zone Healthcare Holdings, LLC | 7.4% | ||||
| Farallon Capital Partners, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.1% | ||||
| Farallon Capital Management, L.L.C. | 7.4% | ||||
| Farallon Partners, L.L.C. | 2.4% | ||||
| Farallon F5 (GP), L.L.C. | 0.1% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Dapice Joshua J. | 9.9% | ||||
| Dreyfuss, Philip D. | 9.9% | ||||
| Dunn Hannah E. | 9.9% | ||||
| Fried, Richard B | 0% | ||||
| Gehani, Varun N. | 9.9% | ||||
| Giauque, Nicolas | 9.9% | ||||
| Husen, Avner A. | 9.9% | ||||
| Kim, David T. | 9.9% | ||||
| Linn, Michael G. | 9.9% | ||||
| Luo Patrick (Cheng) | 9.9% | ||||
| Patel, Rajiv A. | 0% | ||||
| Roberts, Jr., Thomas G. | 9.9% | ||||
| Saito Edric C. | 9.9% | ||||
| Seybold, William | 0% | ||||
| Short Daniel S. | 9.9% | ||||
| Spokes, Andrew J. M. | 9.9% | ||||
| Warren, John R. | 9.9% | ||||
| Wehrly, Mark C. | 9.9% | ||||
|
GRAIL, Inc.
13G/A
Amendment 1
GRAL · 384747101
|
5.9% |
2/9/2026
Event 12/31/2025
|
|||
| Farallon Capital Partners, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.1% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.1% | ||||
| Farallon Healthcare Partners Master, L.P. | 3.4% | ||||
| Farallon Partners, L.L.C. | 5.8% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.1% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 3.4% | ||||
| Dapice Joshua J. | 5.9% | ||||
| Dreyfuss, Philip D. | 5.9% | ||||
| Dunn Hannah E. | 5.9% | ||||
| Fried, Richard B | 0% | ||||
| Gehani, Varun N. | 5.9% | ||||
| Giauque, Nicolas | 5.9% | ||||
| Husen, Avner A. | 5.9% | ||||
| Kim, David T. | 5.9% | ||||
| Linn, Michael G. | 5.9% | ||||
| Luo Patrick (Cheng) | 5.9% | ||||
| Patel, Rajiv A. | 0% | ||||
| Roberts, Jr., Thomas G. | 5.9% | ||||
| Saito Edric C. | 5.9% | ||||
| Seybold, William | 0% | ||||
| Short Daniel S. | 5.9% | ||||
| Spokes, Andrew J. M. | 5.9% | ||||
| Warren, John R. | 5.9% | ||||
| Wehrly, Mark C. | 5.9% | ||||
|
Assembly Biosciences, Inc.
13G/A
Amendment 1
ASMB · 045396207
|
7.8% |
2/9/2026
Event 12/31/2025
|
|||
| Farallon Capital Partners, L.P. | 1.5% | ||||
| Farallon Capital Institutional Partners, L.P. | 1.4% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.3% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.4% | ||||
| Farallon Capital Offshore Investors II, L.P. | 3.1% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.2% | ||||
| Farallon Capital F5 Master I, L.P. | 0.3% | ||||
| Farallon Partners, L.L.C. | 7.4% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.4% | ||||
| Farallon F5 (GP), L.L.C. | 0.3% | ||||
| Dapice Joshua J. | 7.8% | ||||
| Dreyfuss, Philip D. | 7.8% | ||||
| Dunn Hannah E. | 7.8% | ||||
| Fried, Richard B | 0% | ||||
| Gehani, Varun N. | 7.8% | ||||
| Giauque, Nicolas | 7.8% | ||||
| Husen, Avner A. | 7.8% | ||||
| Kim, David T. | 7.8% | ||||
| Linn, Michael G. | 7.8% | ||||
| Luo Patrick (Cheng) | 7.8% | ||||
| Patel, Rajiv A. | 0% | ||||
| Roberts, Jr., Thomas G. | 7.8% | ||||
| Saito Edric C. | 7.8% | ||||
| Seybold, William | 0% | ||||
| Short Daniel S. | 7.8% | ||||
| Spokes, Andrew J. M. | 7.8% | ||||
| Warren, John R. | 7.8% | ||||
| Wehrly, Mark C. | 7.8% | ||||
|
Protagonist Therapeutics, Inc.
13G/A
Amendment 8
PTGX · 74366E102
|
10.0% |
2/6/2026
Event 12/31/2025
|
|||
| Farallon Capital Partners, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.1% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0.9% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.2% | ||||
| Farallon Healthcare Partners Master, L.P. | 7.6% | ||||
| Farallon Partners, L.L.C. | 9.8% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.2% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 7.6% | ||||
| Dapice Joshua J. | 10.0% | ||||
| Dreyfuss, Philip D. | 10.0% | ||||
| Dunn Hannah E. | 10.0% | ||||
| Fried, Richard B | 0% | ||||
| Gehani, Varun N. | 10.0% | ||||
| Giauque, Nicolas | 10.0% | ||||
| Husen, Avner A. | 10.0% | ||||
| Kim, David T. | 10.0% | ||||
| Linn, Michael G. | 10.0% | ||||
| Luo Patrick (Cheng) | 10.0% | ||||
| Patel, Rajiv A. | 0% | ||||
| Roberts, Jr., Thomas G. | 10.0% | ||||
| Saito Edric C. | 10.0% | ||||
| Seybold, William | 0% | ||||
| Short Daniel S. | 10.0% | ||||
| Spokes, Andrew J. M. | 10.0% | ||||
| Warren, John R. | 10.0% | ||||
| Wehrly, Mark C. | 10.0% | ||||
|
Lantheus Holdings, Inc.
13G/A
Amendment 4
CATX · 46489V104
|
8.2% |
2/5/2026
Event 12/31/2025
|
|||
| Farallon Capital Partners, L.P. | 0.6% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.7% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.5% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.2% | ||||
| Farallon Healthcare Partners Master, L.P. | 4.7% | ||||
| Farallon Partners, L.L.C. | 8.0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.2% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 4.7% | ||||
| Dapice Joshua J. | 8.2% | ||||
| Dreyfuss, Philip D. | 8.2% | ||||
| Dunn Hannah E. | 8.2% | ||||
| Fried, Richard B | 0% | ||||
| Gehani, Varun N. | 8.2% | ||||
| Giauque, Nicolas | 8.2% | ||||
| Husen, Avner A. | 8.2% | ||||
| Kim, David T. | 8.2% | ||||
| Linn, Michael G. | 8.2% | ||||
| Luo Patrick (Cheng) | 8.2% | ||||
| Patel, Rajiv A. | 0% | ||||
| Roberts, Jr., Thomas G. | 8.2% | ||||
| Saito Edric C. | 8.2% | ||||
| Seybold, William | 0% | ||||
| Short Daniel S. | 8.2% | ||||
| Spokes, Andrew J. M. | 8.2% | ||||
| Warren, John R. | 8.2% | ||||
| Wehrly, Mark C. | 8.2% | ||||
|
Beam Therapeutics Inc.
13G/A
Amendment 5
BEAM · 07373V105
|
10.0% |
2/5/2026
Event 12/31/2025
|
|||
| Farallon Capital Partners, L.P. | 0.7% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.8% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.6% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.3% | ||||
| Farallon Healthcare Partners Master, L.P. | 6.0% | ||||
| Farallon Partners, L.L.C. | 9.7% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.3% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 6.0% | ||||
| Dapice Joshua J. | 10.0% | ||||
| Dreyfuss, Philip D. | 10.0% | ||||
| Dunn Hannah E. | 10.0% | ||||
| Fried, Richard B | 0% | ||||
| Gehani, Varun N. | 10.0% | ||||
| Giauque, Nicolas | 10.0% | ||||
| Husen, Avner A. | 10.0% | ||||
| Kim, David T. | 10.0% | ||||
| Linn, Michael G. | 10.0% | ||||
| Luo Patrick (Cheng) | 10.0% | ||||
| Patel, Rajiv A. | 0% | ||||
| Roberts, Jr., Thomas G. | 10.0% | ||||
| Saito Edric C. | 10.0% | ||||
| Seybold, William | 0% | ||||
| Short Daniel S. | 10.0% | ||||
| Spokes, Andrew J. M. | 10.0% | ||||
| Warren, John R. | 10.0% | ||||
| Wehrly, Mark C. | 10.0% | ||||
|
Savara Inc.
13G/A
Amendment 10
SVRA · 805111101
|
6.9% |
2/5/2026
Event 12/31/2025
|
|||
| Farallon Capital Partners, L.P. | 1.2% | ||||
| Farallon Capital Institutional Partners, L.P. | 1.9% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.4% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.2% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.3% | ||||
| Farallon Capital Offshore Investors II, L.P. | 2.7% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.5% | ||||
| Farallon Partners, L.L.C. | 6.5% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.3% | ||||
| Farallon F5 (GP), L.L.C. | 0.5% | ||||
| Dapice Joshua J. | 6.9% | ||||
| Dreyfuss, Philip D. | 6.9% | ||||
| Dunn Hannah E. | 6.9% | ||||
| Fried, Richard B | 0% | ||||
| Gehani, Varun N. | 6.9% | ||||
| Giauque, Nicolas | 6.9% | ||||
| Husen, Avner A. | 6.9% | ||||
| Kim, David T. | 6.9% | ||||
| Linn, Michael G. | 6.9% | ||||
| Luo Patrick (Cheng) | 6.9% | ||||
| Patel, Rajiv A. | 0% | ||||
| Roberts, Jr., Thomas G. | 6.9% | ||||
| Saito Edric C. | 6.9% | ||||
| Seybold, William | 0% | ||||
| Short Daniel S. | 6.9% | ||||
| Spokes, Andrew J. M. | 6.9% | ||||
| Warren, John R. | 6.9% | ||||
| Wehrly, Mark C. | 6.9% | ||||
|
Minerva Neurosciences, Inc.
13G/A
Amendment 1
NERV · 603380205
|
10.0% |
2/5/2026
Event 12/31/2025
|
|||
| Farallon Capital Partners, L.P. | 2.0% | ||||
| Farallon Capital Institutional Partners, L.P. | 1.9% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.6% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.4% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.5% | ||||
| Farallon Capital Offshore Investors II, L.P. | 4.2% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.3% | ||||
| Farallon Capital F5 Master I, L.P. | 0.5% | ||||
| Farallon Partners, L.L.C. | 9.5% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.5% | ||||
| Farallon F5 (GP), L.L.C. | 0.5% | ||||
| Dapice Joshua J. | 10.0% | ||||
| Dreyfuss, Philip D. | 10.0% | ||||
| Dunn Hannah E. | 10.0% | ||||
| Fried, Richard B | 0% | ||||
| Gehani, Varun N. | 10.0% | ||||
| Giauque, Nicolas | 10.0% | ||||
| Husen, Avner A. | 10.0% | ||||
| Kim, David T. | 10.0% | ||||
| Linn, Michael G. | 10.0% | ||||
| Luo Patrick (Cheng) | 10.0% | ||||
| Patel, Rajiv A. | 0% | ||||
| Roberts, Jr., Thomas G. | 10.0% | ||||
| Saito Edric C. | 10.0% | ||||
| Seybold, William | 0% | ||||
| Short Daniel S. | 10.0% | ||||
| Spokes, Andrew J. M. | 10.0% | ||||
| Warren, John R. | 10.0% | ||||
| Wehrly, Mark C. | 10.0% | ||||
|
Enanta Pharmaceuticals, Inc.
13G/A
Amendment 7
ENTA · 29251M106
|
9.8% |
2/5/2026
Event 12/31/2025
|
|||
| Farallon Capital Partners, L.P. | 1.8% | ||||
| Farallon Capital Institutional Partners, L.P. | 2.1% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.3% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.4% | ||||
| Farallon Capital Offshore Investors II, L.P. | 3.8% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.2% | ||||
| Farallon Capital F5 Master I, L.P. | 0.6% | ||||
| Farallon Partners, L.L.C. | 9.1% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.4% | ||||
| Farallon F5 (GP), L.L.C. | 0.6% | ||||
| Dapice Joshua J. | 9.8% | ||||
| Dreyfuss, Philip D. | 9.8% | ||||
| Dunn Hannah E. | 9.8% | ||||
| Fried, Richard B | 0% | ||||
| Gehani, Varun N. | 9.8% | ||||
| Giauque, Nicolas | 9.8% | ||||
| Husen, Avner A. | 9.8% | ||||
| Kim, David T. | 9.8% | ||||
| Linn, Michael G. | 9.8% | ||||
| Luo Patrick (Cheng) | 9.8% | ||||
| Patel, Rajiv A. | 0% | ||||
| Roberts, Jr., Thomas G. | 9.8% | ||||
| Saito Edric C. | 9.8% | ||||
| Seybold, William | 0% | ||||
| Short Daniel S. | 9.8% | ||||
| Spokes, Andrew J. M. | 9.8% | ||||
| Warren, John R. | 9.8% | ||||
| Wehrly, Mark C. | 9.8% | ||||
|
Crinetics Pharmaceuticals, Inc.
13G/A
Amendment 1
CRNX · 22663K107
|
8.5% |
2/5/2026
Event 12/31/2025
|
|||
| Farallon Capital Partners, L.P. | 0.6% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.7% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.4% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.2% | ||||
| Farallon Healthcare Partners Master, L.P. | 4.9% | ||||
| Farallon Partners, L.L.C. | 8.2% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.2% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 4.9% | ||||
| Dapice Joshua J. | 8.5% | ||||
| Dreyfuss, Philip D. | 8.5% | ||||
| Dunn Hannah E. | 8.5% | ||||
| Fried, Richard B | 0% | ||||
| Gehani, Varun N. | 8.5% | ||||
| Giauque, Nicolas | 8.5% | ||||
| Husen, Avner A. | 8.5% | ||||
| Kim, David T. | 8.5% | ||||
| Linn, Michael G. | 8.5% | ||||
| Luo Patrick (Cheng) | 8.5% | ||||
| Patel, Rajiv A. | 0% | ||||
| Roberts, Jr., Thomas G. | 8.5% | ||||
| Saito Edric C. | 8.5% | ||||
| Seybold, William | 0% | ||||
| Short Daniel S. | 8.5% | ||||
| Spokes, Andrew J. M. | 8.5% | ||||
| Warren, John R. | 8.5% | ||||
| Wehrly, Mark C. | 8.5% | ||||
|
Exelixis, Inc.
13D/A
Amendment 7
EXEL · 30161Q104
|
5.9% |
1/5/2026
Event 1/1/2026
|
|||
| Farallon Capital Partners, L.P. | 0.4% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.1% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0.9% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.2% | ||||
| Farallon Healthcare Partners Master, L.P. | 3.4% | ||||
| Farallon Partners, L.L.C. | 5.7% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.2% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 3.4% | ||||
| Dapice Joshua J. | 5.9% | ||||
| Dreyfuss, Philip D. | 5.9% | ||||
| Dunn Hannah E. | 5.9% | ||||
| Fried, Richard B | 0% | ||||
| Gehani, Varun N. | 5.9% | ||||
| Giauque, Nicolas | 5.9% | ||||
| Husen, Avner A. | 5.9% | ||||
| Kim, David T. | 5.9% | ||||
| Linn, Michael G. | 5.9% | ||||
| Luo Patrick (Cheng) | 5.9% | ||||
| Patel, Rajiv A. | 0% | ||||
| Roberts, Jr., Thomas G. | 5.9% | ||||
| Saito Edric C. | 5.9% | ||||
| Seybold, William | 0% | ||||
| Short Daniel S. | 5.9% | ||||
| Spokes, Andrew J. M. | 5.9% | ||||
| Warren, John R. | 5.9% | ||||
| Wehrly, Mark C. | 5.9% | ||||
|
Minerva Neurosciences, Inc.
13G
NERV · 603380205
|
10.0% |
12/29/2025
Event 12/22/2025
|
|||
| Farallon Capital Partners, L.P. | 2.0% | ||||
| Farallon Capital Institutional Partners, L.P. | 1.9% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.6% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.4% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.5% | ||||
| Farallon Capital Offshore Investors II, L.P. | 4.2% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.3% | ||||
| Farallon Capital F5 Master I, L.P. | 0.5% | ||||
| Farallon Partners, L.L.C. | 9.5% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.5% | ||||
| Farallon F5 (GP), L.L.C. | 0.5% | ||||
| Dapice Joshua J. | 10.0% | ||||
| Dreyfuss, Philip D. | 10.0% | ||||
| Dunn Hannah E. | 10.0% | ||||
| Fried, Richard B | 10.0% | ||||
| Gehani, Varun N. | 10.0% | ||||
| Giauque, Nicolas | 10.0% | ||||
| Kim, David T. | 10.0% | ||||
| Linn, Michael G. | 10.0% | ||||
| Luo Patrick (Cheng) | 10.0% | ||||
| Patel, Rajiv A. | 10.0% | ||||
| Roberts, Jr., Thomas G. | 10.0% | ||||
| Saito Edric C. | 10.0% | ||||
| Seybold, William | 10.0% | ||||
| Short Daniel S. | 10.0% | ||||
| Spokes, Andrew J. M. | 10.0% | ||||
| Warren, John R. | 10.0% | ||||
| Wehrly, Mark C. | 10.0% | ||||
|
GRAIL, Inc.
13G
GRAL · 384747101
|
5.5% |
11/24/2025
Event 11/17/2025
|
|||
| Farallon Capital Partners, L.P. | 0.4% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.1% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.1% | ||||
| Farallon Healthcare Partners Master, L.P. | 3.1% | ||||
| Farallon Partners, L.L.C. | 5.4% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.1% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 3.1% | ||||
| Dapice Joshua J. | 5.5% | ||||
| Dreyfuss, Philip D. | 5.5% | ||||
| Dunn Hannah E. | 5.5% | ||||
| Fried, Richard B | 5.5% | ||||
| Gehani, Varun N. | 5.5% | ||||
| Giauque, Nicolas | 5.5% | ||||
| Kim, David T. | 5.5% | ||||
| Linn, Michael G. | 5.5% | ||||
| Luo Patrick (Cheng) | 5.5% | ||||
| Patel, Rajiv A. | 5.5% | ||||
| Roberts, Jr., Thomas G. | 5.5% | ||||
| Saito Edric C. | 5.5% | ||||
| Seybold, William | 5.5% | ||||
| Short Daniel S. | 5.5% | ||||
| Spokes, Andrew J. M. | 5.5% | ||||
| Warren, John R. | 5.5% | ||||
| Wehrly, Mark C. | 5.5% | ||||
|
GRAIL, Inc.
13G
GRAL · 384747101
|
4.9% |
11/13/2025
Event 10/21/2025
|
|||
| Farallon Capital Partners, L.P. | 0.4% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.4% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.1% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0.8% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.1% | ||||
| Farallon Healthcare Partners Master, L.P. | 2.9% | ||||
| Farallon Partners, L.L.C. | 4.9% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.1% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 2.9% | ||||
| Dapice Joshua J. | 4.9% | ||||
| Dreyfuss, Philip D. | 4.9% | ||||
| Dunn Hannah E. | 4.9% | ||||
| Fried, Richard B | 4.9% | ||||
| Gehani, Varun N. | 4.9% | ||||
| Giauque, Nicolas | 4.9% | ||||
| Kim, David T. | 4.9% | ||||
| Linn, Michael G. | 4.9% | ||||
| Luo Patrick (Cheng) | 4.9% | ||||
| Patel, Rajiv A. | 4.9% | ||||
| Roberts, Jr., Thomas G. | 4.9% | ||||
| Saito Edric C. | 4.9% | ||||
| Seybold, William | 4.9% | ||||
| Short Daniel S. | 4.9% | ||||
| Spokes, Andrew J. M. | 4.9% | ||||
| Warren, John R. | 4.9% | ||||
| Wehrly, Mark C. | 4.9% | ||||
|
Lantheus Holdings, Inc.
13G/A
Amendment 3
CATX · 46489V104
|
5.1% |
11/12/2025
Event 9/30/2025
|
|||
| Farallon Capital Partners, L.P. | 0.4% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.1% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0.9% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.1% | ||||
| Farallon Healthcare Partners Master, L.P. | 2.8% | ||||
| Farallon Partners, L.L.C. | 5.0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.1% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 2.8% | ||||
| Dapice Joshua J. | 5.1% | ||||
| Dreyfuss, Philip D. | 5.1% | ||||
| Dunn Hannah E. | 5.1% | ||||
| Fried, Richard B | 5.1% | ||||
| Gehani, Varun N. | 5.1% | ||||
| Giauque, Nicolas | 5.1% | ||||
| Kim, David T. | 5.1% | ||||
| Linn, Michael G. | 5.1% | ||||
| Luo Patrick (Cheng) | 5.1% | ||||
| Patel, Rajiv A. | 5.1% | ||||
| Roberts, Jr., Thomas G. | 5.1% | ||||
| Saito Edric C. | 5.1% | ||||
| Seybold, William | 5.1% | ||||
| Short Daniel S. | 5.1% | ||||
| Spokes, Andrew J. M. | 5.1% | ||||
| Warren, John R. | 5.1% | ||||
| Wehrly, Mark C. | 5.1% | ||||
|
Tango Therapeutics, Inc.
13G/A
Amendment 2
TNGX · 87583X109
|
9.7% |
11/12/2025
Event 9/30/2025
|
|||
| Farallon Capital Partners, L.P. | 1.6% | ||||
| Farallon Capital Institutional Partners, L.P. | 2.1% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.4% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.5% | ||||
| Farallon Capital Offshore Investors II, L.P. | 4.0% | ||||
| Farallon Capital F5 Master I, L.P. | 0.4% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.3% | ||||
| Farallon Partners, L.L.C. | 9.3% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.5% | ||||
| Farallon F5 (GP), L.L.C. | 0.4% | ||||
| Dapice Joshua J. | 9.7% | ||||
| Dreyfuss, Philip D. | 9.7% | ||||
| Dunn Hannah E. | 9.7% | ||||
| Fried, Richard B | 9.7% | ||||
| Gehani, Varun N. | 9.7% | ||||
| Giauque, Nicolas | 9.7% | ||||
| Kim, David T. | 9.7% | ||||
| Linn, Michael G. | 9.7% | ||||
| Luo Patrick (Cheng) | 9.7% | ||||
| Patel, Rajiv A. | 9.7% | ||||
| Roberts, Jr., Thomas G. | 9.7% | ||||
| Saito Edric C. | 9.7% | ||||
| Seybold, William | 9.7% | ||||
| Short Daniel S. | 9.7% | ||||
| Spokes, Andrew J. M. | 9.7% | ||||
| Warren, John R. | 9.7% | ||||
| Wehrly, Mark C. | 9.7% | ||||
|
Liquidia Corporation
13G/A
Amendment 1
LQDA · 53635D202
|
10.0% |
11/12/2025
Event 9/30/2025
|
|||
| Farallon Capital Partners, L.P. | 0.9% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.8% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.3% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.2% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.2% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.9% | ||||
| Farallon Capital F5 Master I, L.P. | 0.2% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Healthcare Partners Master, L.P. | 5.3% | ||||
| Farallon Partners, L.L.C. | 9.7% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.2% | ||||
| Farallon F5 (GP), L.L.C. | 0.2% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 5.3% | ||||
| Dapice Joshua J. | 10.0% | ||||
| Dreyfuss, Philip D. | 10.0% | ||||
| Dunn Hannah E. | 10.0% | ||||
| Fried, Richard B | 10.0% | ||||
| Gehani, Varun N. | 10.0% | ||||
| Giauque, Nicolas | 10.0% | ||||
| Kim, David T. | 10.0% | ||||
| Linn, Michael G. | 10.0% | ||||
| Luo Patrick (Cheng) | 10.0% | ||||
| Patel, Rajiv A. | 10.0% | ||||
| Roberts, Jr., Thomas G. | 10.0% | ||||
| Saito Edric C. | 10.0% | ||||
| Seybold, William | 10.0% | ||||
| Short Daniel S. | 10.0% | ||||
| Spokes, Andrew J. M. | 10.0% | ||||
| Warren, John R. | 10.0% | ||||
| Wehrly, Mark C. | 10.0% | ||||
|
Crinetics Pharmaceuticals, Inc.
13G
CRNX · 22663K107
|
6.0% |
9/8/2025
Event 8/29/2025
|
|||
| Farallon Capital Partners, L.P. | 0.4% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.1% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.2% | ||||
| Farallon Healthcare Partners Master, L.P. | 3.5% | ||||
| Farallon Partners, L.L.C. | 5.8% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.2% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 3.5% | ||||
| Dapice Joshua J. | 6.0% | ||||
| Dreyfuss, Philip D. | 6.0% | ||||
| Dunn Hannah E. | 6.0% | ||||
| Fried, Richard B | 6.0% | ||||
| Gehani, Varun N. | 6.0% | ||||
| Giauque, Nicolas | 6.0% | ||||
| Kim, David T. | 6.0% | ||||
| Linn, Michael G. | 6.0% | ||||
| Luo Patrick (Cheng) | 6.0% | ||||
| Patel, Rajiv A. | 6.0% | ||||
| Roberts, Jr., Thomas G. | 6.0% | ||||
| Saito Edric C. | 6.0% | ||||
| Seybold, William | 6.0% | ||||
| Short Daniel S. | 6.0% | ||||
| Spokes, Andrew J. M. | 6.0% | ||||
| Warren, John R. | 6.0% | ||||
| Wehrly, Mark C. | 6.0% | ||||
|
Assembly Biosciences, Inc.
13G
ASMB · 045396207
|
7.3% |
8/15/2025
Event 8/8/2025
|
|||
| Farallon Capital Partners, L.P. | 1.4% | ||||
| Farallon Capital Institutional Partners, L.P. | 1.3% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.4% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.3% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.3% | ||||
| Farallon Capital Offshore Investors II, L.P. | 3.0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.2% | ||||
| Farallon Capital F5 Master I, L.P. | 0.3% | ||||
| Farallon Partners, L.L.C. | 7.0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.3% | ||||
| Farallon F5 (GP), L.L.C. | 0.3% | ||||
| Dapice Joshua J. | 7.3% | ||||
| Dreyfuss, Philip D. | 7.3% | ||||
| Dunn Hannah E. | 7.3% | ||||
| Fried, Richard B | 7.3% | ||||
| Gehani, Varun N. | 7.3% | ||||
| Giauque, Nicolas | 7.3% | ||||
| Kim, David T. | 7.3% | ||||
| Linn, Michael G. | 7.3% | ||||
| Luo Patrick (Cheng) | 7.3% | ||||
| Patel, Rajiv A. | 7.3% | ||||
| Roberts, Jr., Thomas G. | 7.3% | ||||
| Saito Edric C. | 7.3% | ||||
| Seybold, William | 7.3% | ||||
| Short Daniel S. | 7.3% | ||||
| Spokes, Andrew J. M. | 7.3% | ||||
| Warren, John R. | 7.3% | ||||
| Wehrly, Mark C. | 7.3% | ||||
|
Tango Therapeutics, Inc.
13G/A
Amendment 1
TNGX · 87583X109
|
8.4% |
8/13/2025
Event 6/30/2025
|
|||
| Farallon Capital Partners, L.P. | 1.4% | ||||
| Farallon Capital Institutional Partners, L.P. | 1.9% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.3% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.4% | ||||
| Farallon Capital Offshore Investors II, L.P. | 3.5% | ||||
| Farallon Capital F5 Master I, L.P. | 0.3% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.2% | ||||
| Farallon Partners, L.L.C. | 8.1% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.4% | ||||
| Farallon F5 (GP), L.L.C. | 0.3% | ||||
| Dapice Joshua J. | 8.4% | ||||
| Dreyfuss, Philip D. | 8.4% | ||||
| Dunn Hannah E. | 8.4% | ||||
| Fried, Richard B | 8.4% | ||||
| Gehani, Varun N. | 8.4% | ||||
| Giauque, Nicolas | 8.4% | ||||
| Kim, David T. | 8.4% | ||||
| Linn, Michael G. | 8.4% | ||||
| Luo Patrick (Cheng) | 8.4% | ||||
| Patel, Rajiv A. | 8.4% | ||||
| Roberts, Jr., Thomas G. | 8.4% | ||||
| Saito Edric C. | 8.4% | ||||
| Seybold, William | 8.4% | ||||
| Short Daniel S. | 8.4% | ||||
| Spokes, Andrew J. M. | 8.4% | ||||
| Warren, John R. | 8.4% | ||||
| Wehrly, Mark C. | 8.4% | ||||
|
Beta Bionics, Inc.
13G/A
Amendment 1
BBNX · 08659B102
|
9.7% |
8/13/2025
Event 6/30/2025
|
|||
| Zone Healthcare Holdings, LLC | 7.6% | ||||
| Farallon Capital Partners, L.P. | 0.4% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.4% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.1% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0.9% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.1% | ||||
| Farallon Capital Management, L.L.C. | 7.6% | ||||
| Farallon Partners, L.L.C. | 2.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.1% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Dapice Joshua J. | 9.7% | ||||
| Dreyfuss, Philip D. | 9.7% | ||||
| Dunn Hannah E. | 9.7% | ||||
| Fried, Richard B | 9.7% | ||||
| Gehani, Varun N. | 9.7% | ||||
| Giauque, Nicolas | 9.7% | ||||
| Kim, David T. | 9.7% | ||||
| Linn, Michael G. | 9.7% | ||||
| Luo Patrick (Cheng) | 9.7% | ||||
| Patel, Rajiv A. | 9.7% | ||||
| Roberts, Jr., Thomas G. | 9.7% | ||||
| Saito Edric C. | 9.7% | ||||
| Seybold, William | 9.7% | ||||
| Short Daniel S. | 9.7% | ||||
| Spokes, Andrew J. M. | 9.7% | ||||
| Warren, John R. | 9.7% | ||||
| Wehrly, Mark C. | 9.7% | ||||
|
The New York Times Company
13G/A
Amendment 1
NYT · 650111107
|
3.5% |
8/12/2025
Event 6/30/2025
|
|||
| Farallon Capital Partners, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.1% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0.4% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0.1% | ||||
| Farallon Equity Partners Master, L.P. | 2.4% | ||||
| Farallon Partners, L.L.C. | 3.4% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||||
| Farallon F5 (GP), L.L.C. | 0.1% | ||||
| Farallon Equity Partners (GP), L.L.C. | 2.4% | ||||
| Dapice Joshua J. | 3.5% | ||||
| Dreyfuss, Philip D. | 3.5% | ||||
| Dunn Hannah E. | 3.5% | ||||
| Fried, Richard B | 3.5% | ||||
| Gehani, Varun N. | 3.5% | ||||
| Giauque, Nicolas | 3.5% | ||||
| Kim, David T. | 3.5% | ||||
| Linn, Michael G. | 3.5% | ||||
| Luo Patrick (Cheng) | 3.5% | ||||
| Patel, Rajiv A. | 3.5% | ||||
| Roberts, Jr., Thomas G. | 3.5% | ||||
| Saito Edric C. | 3.5% | ||||
| Seybold, William | 3.5% | ||||
| Short Daniel S. | 3.5% | ||||
| Spokes, Andrew J. M. | 3.5% | ||||
| Warren, John R. | 3.5% | ||||
| Wehrly, Mark C. | 3.5% | ||||
|
Aramark
13G/A
Amendment 2
ARMK · 03852U106
|
4.9% |
8/12/2025
Event 6/30/2025
|
|||
| Farallon Capital Partners, L.P. | 0.3% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.3% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.1% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0.6% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0.1% | ||||
| Farallon Equity Partners Master, L.P. | 3.5% | ||||
| Farallon Partners, L.L.C. | 4.8% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.1% | ||||
| Farallon Equity Partners (GP), L.L.C. | 3.5% | ||||
| Dapice Joshua J. | 4.9% | ||||
| Dreyfuss, Philip D. | 4.9% | ||||
| Dunn Hannah E. | 4.9% | ||||
| Fried, Richard B | 4.9% | ||||
| Gehani, Varun N. | 4.9% | ||||
| Giauque, Nicolas | 4.9% | ||||
| Kim, David T. | 4.9% | ||||
| Linn, Michael G. | 4.9% | ||||
| Luo Patrick (Cheng) | 4.9% | ||||
| Patel, Rajiv A. | 4.9% | ||||
| Roberts, Jr., Thomas G. | 4.9% | ||||
| Saito Edric C. | 4.9% | ||||
| Seybold, William | 4.9% | ||||
| Short Daniel S. | 4.9% | ||||
| Spokes, Andrew J. M. | 4.9% | ||||
| Warren, John R. | 4.9% | ||||
| Wehrly, Mark C. | 4.9% | ||||
|
Liquidia Corporation
13G
LQDA · 53635D202
|
8.0% |
7/11/2025
Event 7/7/2025
|
|||
| Farallon Capital Partners, L.P. | 0.9% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.8% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.3% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.2% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.2% | ||||
| Farallon Capital Offshore Investors II, L.P. | 2.0% | ||||
| Farallon Capital F5 Master I, L.P. | 0.2% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Healthcare Partners Master, L.P. | 3.0% | ||||
| Farallon Partners, L.L.C. | 7.7% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.2% | ||||
| Farallon F5 (GP), L.L.C. | 0.2% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 3.0% | ||||
| Dapice Joshua J. | 8.0% | ||||
| Dreyfuss, Philip D. | 8.0% | ||||
| Dunn Hannah E. | 8.0% | ||||
| Fried, Richard B | 8.0% | ||||
| Gehani, Varun N. | 8.0% | ||||
| Giauque, Nicolas | 8.0% | ||||
| Kim, David T. | 8.0% | ||||
| Linn, Michael G. | 8.0% | ||||
| Luo Patrick (Cheng) | 8.0% | ||||
| Patel, Rajiv A. | 8.0% | ||||
| Roberts, Jr., Thomas G. | 8.0% | ||||
| Saito Edric C. | 8.0% | ||||
| Seybold, William | 8.0% | ||||
| Short Daniel S. | 8.0% | ||||
| Spokes, Andrew J. M. | 8.0% | ||||
| Warren, John R. | 8.0% | ||||
| Wehrly, Mark C. | 8.0% | ||||
|
23andMe Holding Co.
13G
MEHCQ · 90138Q306
|
6.2% |
6/20/2025
Event 6/13/2025
|
|||
| Farallon Capital Partners, L.P. | 1.1% | ||||
| Farallon Capital Institutional Partners, L.P. | 1.0% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.3% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.3% | ||||
| Farallon Capital Offshore Investors II, L.P. | 2.6% | ||||
| Farallon Capital F5 Master I, L.P. | 0.2% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.2% | ||||
| Farallon Partners, L.L.C. | 6.0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.3% | ||||
| Farallon F5 (GP), L.L.C. | 0.2% | ||||
| Dapice Joshua J. | 6.2% | ||||
| Dreyfuss, Philip D. | 6.2% | ||||
| Dunn Hannah E. | 6.2% | ||||
| Fried, Richard B | 6.2% | ||||
| Gehani, Varun N. | 6.2% | ||||
| Giauque, Nicolas | 6.2% | ||||
| Kim, David T. | 6.2% | ||||
| Linn, Michael G. | 6.2% | ||||
| Luo Patrick (Cheng) | 6.2% | ||||
| Patel, Rajiv A. | 6.2% | ||||
| Roberts, Jr., Thomas G. | 6.2% | ||||
| Saito Edric C. | 6.2% | ||||
| Seybold, William | 6.2% | ||||
| Short Daniel S. | 6.2% | ||||
| Spokes, Andrew J. M. | 6.2% | ||||
| Warren, John R. | 6.2% | ||||
| Wehrly, Mark C. | 6.2% | ||||
|
Tango Therapeutics, Inc.
13G
TNGX · 87583X109
|
6.6% |
6/13/2025
Event 6/6/2025
|
|||
| Farallon Capital Partners, L.P. | 1.1% | ||||
| Farallon Capital Institutional Partners, L.P. | 1.5% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.3% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.2% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.3% | ||||
| Farallon Capital Offshore Investors II, L.P. | 2.8% | ||||
| Farallon Capital F5 Master I, L.P. | 0.3% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.2% | ||||
| Farallon Partners, L.L.C. | 6.4% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.3% | ||||
| Farallon F5 (GP), L.L.C. | 0.3% | ||||
| Dapice Joshua J. | 6.6% | ||||
| Dreyfuss, Philip D. | 6.6% | ||||
| Dunn Hannah E. | 6.6% | ||||
| Fried, Richard B | 6.6% | ||||
| Gehani, Varun N. | 6.6% | ||||
| Giauque, Nicolas | 6.6% | ||||
| Kim, David T. | 6.6% | ||||
| Linn, Michael G. | 6.6% | ||||
| Luo Patrick (Cheng) | 6.6% | ||||
| Patel, Rajiv A. | 6.6% | ||||
| Roberts, Jr., Thomas G. | 6.6% | ||||
| Saito Edric C. | 6.6% | ||||
| Seybold, William | 6.6% | ||||
| Short Daniel S. | 6.6% | ||||
| Spokes, Andrew J. M. | 6.6% | ||||
| Warren, John R. | 6.6% | ||||
| Wehrly, Mark C. | 6.6% | ||||
|
Exelixis, Inc.
13D/A
Amendment 6
EXEL · 30161Q104
|
6.8% |
5/20/2025
Event 5/16/2025
|
|||
| Farallon Capital Partners, L.P. | 0.6% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.7% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.2% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.2% | ||||
| Farallon Healthcare Partners Master, L.P. | 3.7% | ||||
| Farallon Partners, L.L.C. | 6.6% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.2% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 3.7% | ||||
| Dapice Joshua J. | 6.8% | ||||
| Dreyfuss, Philip D. | 6.8% | ||||
| Dunn Hannah E. | 6.8% | ||||
| Fried, Richard B | 6.8% | ||||
| Gehani, Varun N. | 6.8% | ||||
| Giauque, Nicolas | 6.8% | ||||
| Kim, David T. | 6.8% | ||||
| Linn, Michael G. | 6.8% | ||||
| Luo Patrick (Cheng) | 6.8% | ||||
| Patel, Rajiv A. | 6.8% | ||||
| Roberts, Jr., Thomas G. | 6.8% | ||||
| Saito Edric C. | 6.8% | ||||
| Seybold, William | 6.8% | ||||
| Short Daniel S. | 6.8% | ||||
| Spokes, Andrew J. M. | 6.8% | ||||
| Warren, John R. | 6.8% | ||||
| Wehrly, Mark C. | 6.8% | ||||
|
Revolution Medicines, Inc.
13G/A
Amendment 2
RVMD · 76155X100
|
7.9% |
5/15/2025
Event 12/31/2024
|
|||
| Farallon Capital Partners, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.7% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.3% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.3% | ||||
| Farallon Healthcare Partners Master, L.P. | 4.7% | ||||
| Farallon Partners, L.L.C. | 7.6% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.3% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 4.7% | ||||
| Dapice Joshua J. | 7.9% | ||||
| Dreyfuss, Philip D. | 7.9% | ||||
| Dunn Hannah E. | 7.9% | ||||
| Fried, Richard B | 7.9% | ||||
| Gehani, Varun N. | 7.9% | ||||
| Giauque, Nicolas | 7.9% | ||||
| Kim, David T. | 7.9% | ||||
| Linn, Michael G. | 7.9% | ||||
| Luo Patrick (Cheng) | 7.9% | ||||
| Patel, Rajiv A. | 7.9% | ||||
| Roberts, Jr., Thomas G. | 7.9% | ||||
| Saito Edric C. | 7.9% | ||||
| Seybold, William | 7.9% | ||||
| Short Daniel S. | 7.9% | ||||
| Spokes, Andrew J. M. | 7.9% | ||||
| Warren, John R. | 7.9% | ||||
| Wehrly, Mark C. | 7.9% | ||||
|
Revolution Medicines, Inc.
13G/A
Amendment 1
RVMD · 76155X100
|
6.9% |
5/15/2025
Event 9/30/2024
|
|||
| Farallon Capital Partners, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.6% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.1% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.2% | ||||
| Farallon Healthcare Partners Master, L.P. | 3.9% | ||||
| Farallon Partners, L.L.C. | 6.5% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.2% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 3.9% | ||||
| Dapice Joshua J. | 6.8% | ||||
| Dreyfuss, Philip D. | 6.8% | ||||
| Dunn Hannah E. | 6.8% | ||||
| Fried, Richard B | 6.8% | ||||
| Gehani, Varun N. | 6.8% | ||||
| Giauque, Nicolas | 6.9% | ||||
| Kim, David T. | 6.8% | ||||
| Linn, Michael G. | 6.8% | ||||
| Patel, Rajiv A. | 6.8% | ||||
| Roberts, Jr., Thomas G. | 6.8% | ||||
| Saito Edric C. | 6.8% | ||||
| Seybold, William | 6.8% | ||||
| Short Daniel S. | 6.8% | ||||
| Spokes, Andrew J. M. | 6.8% | ||||
| Warren, John R. | 6.8% | ||||
| Wehrly, Mark C. | 6.8% | ||||
|
Revolution Medicines, Inc.
13G
RVMD · 76155X100
|
5.1% |
5/15/2025
Event 4/12/2024
|
|||
| Farallon Capital Partners, L.P. | 0.3% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.1% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0.9% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.2% | ||||
| Farallon Healthcare Partners Master, L.P. | 2.9% | ||||
| Farallon Partners, L.L.C. | 4.9% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.2% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 2.9% | ||||
| Dapice Joshua J. | 5.1% | ||||
| Dreyfuss, Philip D. | 5.1% | ||||
| Dunn Hannah E. | 5.1% | ||||
| Fried, Richard B | 5.1% | ||||
| Gehani, Varun N. | 5.1% | ||||
| Giauque, Nicolas | 5.1% | ||||
| Kim, David T. | 5.1% | ||||
| Linn, Michael G. | 5.1% | ||||
| Patel, Rajiv A. | 5.1% | ||||
| Roberts, Jr., Thomas G. | 5.1% | ||||
| Saito Edric C. | 5.1% | ||||
| Seybold, William | 5.1% | ||||
| Short Daniel S. | 5.1% | ||||
| Spokes, Andrew J. M. | 5.1% | ||||
| Warren, John R. | 5.1% | ||||
| Wehrly, Mark C. | 5.1% | ||||
|
Beam Therapeutics Inc.
13G/A
Amendment 4
BEAM · 07373V105
|
10.0% |
5/13/2025
Event 3/31/2025
|
|||
| Farallon Capital Partners, L.P. | 0.7% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.9% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.2% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.7% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.3% | ||||
| Farallon Healthcare Partners Master, L.P. | 5.8% | ||||
| Farallon Partners, L.L.C. | 9.6% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.2% | ||||
| Farallon F5 (GP), L.L.C. | 0.3% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 5.8% | ||||
| Dapice Joshua J. | 10.0% | ||||
| Dreyfuss, Philip D. | 10.0% | ||||
| Dunn Hannah E. | 10.0% | ||||
| Fried, Richard B | 10.0% | ||||
| Gehani, Varun N. | 10.0% | ||||
| Giauque, Nicolas | 10.0% | ||||
| Kim, David T. | 10.0% | ||||
| Linn, Michael G. | 10.0% | ||||
| Luo Patrick (Cheng) | 10.0% | ||||
| Patel, Rajiv A. | 10.0% | ||||
| Roberts, Jr., Thomas G. | 10.0% | ||||
| Saito Edric C. | 10.0% | ||||
| Seybold, William | 10.0% | ||||
| Short Daniel S. | 10.0% | ||||
| Spokes, Andrew J. M. | 10.0% | ||||
| Warren, John R. | 10.0% | ||||
| Wehrly, Mark C. | 10.0% | ||||
|
Lantheus Holdings, Inc.
13G/A
Amendment 2
CATX · 46489V104
|
8.8% |
5/8/2025
Event 3/31/2025
|
|||
| Farallon Capital Partners, L.P. | 0.7% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.8% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.5% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.2% | ||||
| Farallon Healthcare Partners Master, L.P. | 5.1% | ||||
| Farallon Partners, L.L.C. | 8.6% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.2% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 5.1% | ||||
| Dapice Joshua J. | 8.8% | ||||
| Dreyfuss, Philip D. | 8.8% | ||||
| Dunn Hannah E. | 8.8% | ||||
| Fried, Richard B | 8.8% | ||||
| Gehani, Varun N. | 8.8% | ||||
| Giauque, Nicolas | 8.8% | ||||
| Kim, David T. | 8.8% | ||||
| Linn, Michael G. | 8.8% | ||||
| Luo Patrick (Cheng) | 8.8% | ||||
| Patel, Rajiv A. | 8.8% | ||||
| Roberts, Jr., Thomas G. | 8.8% | ||||
| Saito Edric C. | 8.8% | ||||
| Seybold, William | 8.8% | ||||
| Short Daniel S. | 8.8% | ||||
| Spokes, Andrew J. M. | 8.8% | ||||
| Warren, John R. | 8.8% | ||||
| Wehrly, Mark C. | 8.8% | ||||
|
Aramark
13G/A
Amendment 1
ARMK · 03852U106
|
6.1% |
5/7/2025
Event 3/31/2025
|
|||
| Farallon Capital Partners, L.P. | 0.3% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.4% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.1% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0.8% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0.1% | ||||
| Farallon Equity Partners Master, L.P. | 4.2% | ||||
| Farallon Partners, L.L.C. | 6.0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.1% | ||||
| Farallon Equity Partners (GP), L.L.C. | 4.2% | ||||
| Dapice Joshua J. | 6.1% | ||||
| Dreyfuss, Philip D. | 6.1% | ||||
| Dunn Hannah E. | 6.1% | ||||
| Fried, Richard B | 6.1% | ||||
| Gehani, Varun N. | 6.1% | ||||
| Giauque, Nicolas | 6.1% | ||||
| Kim, David T. | 6.1% | ||||
| Linn, Michael G. | 6.1% | ||||
| Luo Patrick (Cheng) | 6.1% | ||||
| Patel, Rajiv A. | 6.1% | ||||
| Roberts, Jr., Thomas G. | 6.1% | ||||
| Saito Edric C. | 6.1% | ||||
| Seybold, William | 6.1% | ||||
| Short Daniel S. | 6.1% | ||||
| Spokes, Andrew J. M. | 6.1% | ||||
| Warren, John R. | 6.1% | ||||
| Wehrly, Mark C. | 6.1% | ||||
|
Elevation Oncology, Inc.
13G/A
Amendment 3
ELEV · 28623U101
|
0% |
5/7/2025
Event 3/31/2025
|
|||
| Farallon Capital Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners, L.P. | 0% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Partners, L.L.C. | 0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||||
| Farallon F5 (GP), L.L.C. | 0% | ||||
| Dapice Joshua J. | 0% | ||||
| Dreyfuss, Philip D. | 0% | ||||
| Dunn Hannah E. | 0% | ||||
| Fried, Richard B | 0% | ||||
| Gehani, Varun N. | 0% | ||||
| Giauque, Nicolas | 0% | ||||
| Kim, David T. | 0% | ||||
| Linn, Michael G. | 0% | ||||
| Luo Patrick (Cheng) | 0% | ||||
| Patel, Rajiv A. | 0% | ||||
| Roberts, Jr., Thomas G. | 0% | ||||
| Saito Edric C. | 0% | ||||
| Seybold, William | 0% | ||||
| Short Daniel S. | 0% | ||||
| Spokes, Andrew J. M. | 0% | ||||
| Warren, John R. | 0% | ||||
| Wehrly, Mark C. | 0% | ||||
|
Exelixis, Inc.
13D/A
Amendment 5
EXEL · 30161Q104
|
8.4% |
3/5/2025
Event 3/5/2025
|
|||
| Farallon Capital Partners, L.P. | 0.6% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.7% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.3% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.3% | ||||
| Farallon Healthcare Partners Master, L.P. | 5.0% | ||||
| Farallon Partners, L.L.C. | 8.1% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.3% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 5.0% | ||||
| Dapice Joshua J. | 8.4% | ||||
| Dreyfuss, Philip D. | 8.4% | ||||
| Dunn Hannah E. | 8.4% | ||||
| Fried, Richard B | 8.4% | ||||
| Gehani, Varun N. | 8.4% | ||||
| Giauque, Nicolas | 8.4% | ||||
| Kim, David T. | 8.4% | ||||
| Linn, Michael G. | 8.4% | ||||
| Luo Patrick (Cheng) | 8.4% | ||||
| Patel, Rajiv A. | 8.4% | ||||
| Roberts, Jr., Thomas G. | 8.4% | ||||
| Saito Edric C. | 8.4% | ||||
| Seybold, William | 8.4% | ||||
| Short Daniel S. | 8.4% | ||||
| Spokes, Andrew J. M. | 8.4% | ||||
| Warren, John R. | 8.4% | ||||
| Wehrly, Mark C. | 8.4% | ||||
|
Aramark
13G
ARMK · 03852U106
|
5.1% |
2/18/2025
Event 2/11/2025
|
|||
| Farallon Capital Partners, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.3% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.1% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0.6% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0.1% | ||||
| Farallon Equity Partners Master, L.P. | 3.7% | ||||
| Farallon Partners, L.L.C. | 5.0% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||||
| Farallon F5 (GP), L.L.C. | 0.1% | ||||
| Farallon Equity Partners (GP), L.L.C. | 3.7% | ||||
| Dapice Joshua J. | 5.1% | ||||
| Dreyfuss, Philip D. | 5.1% | ||||
| Dunn Hannah E. | 5.1% | ||||
| Fried, Richard B | 5.1% | ||||
| Gehani, Varun N. | 5.1% | ||||
| Giauque, Nicolas | 5.1% | ||||
| Kim, David T. | 5.1% | ||||
| Linn, Michael G. | 5.1% | ||||
| Luo Patrick (Cheng) | 5.1% | ||||
| Patel, Rajiv A. | 5.1% | ||||
| Roberts, Jr., Thomas G. | 5.1% | ||||
| Saito Edric C. | 5.1% | ||||
| Seybold, William | 5.1% | ||||
| Short Daniel S. | 5.1% | ||||
| Spokes, Andrew J. M. | 5.1% | ||||
| Warren, John R. | 5.1% | ||||
| Wehrly, Mark C. | 5.1% | ||||
|
The New York Times Company
13G
NYT · 650111107
|
5.5% |
2/18/2025
Event 2/11/2025
|
|||
| Farallon Capital Partners, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.3% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.1% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0.6% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0.1% | ||||
| Farallon Equity Partners Master, L.P. | 4.0% | ||||
| Farallon Partners, L.L.C. | 5.4% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.1% | ||||
| Farallon Equity Partners (GP), L.L.C. | 4.0% | ||||
| Dapice Joshua J. | 5.5% | ||||
| Dreyfuss, Philip D. | 5.5% | ||||
| Dunn Hannah E. | 5.5% | ||||
| Fried, Richard B | 5.5% | ||||
| Gehani, Varun N. | 5.5% | ||||
| Giauque, Nicolas | 5.5% | ||||
| Kim, David T. | 5.5% | ||||
| Linn, Michael G. | 5.5% | ||||
| Luo Patrick (Cheng) | 5.5% | ||||
| Patel, Rajiv A. | 5.5% | ||||
| Roberts, Jr., Thomas G. | 5.5% | ||||
| Saito Edric C. | 5.5% | ||||
| Seybold, William | 5.5% | ||||
| Short Daniel S. | 5.5% | ||||
| Spokes, Andrew J. M. | 5.5% | ||||
| Warren, John R. | 5.5% | ||||
| Wehrly, Mark C. | 5.5% | ||||
|
Savara Inc.
13G/A
Amendment 9
SVRA · 805111101
|
10.0% |
2/11/2025
Event 12/31/2024
|
|||
| Farallon Capital Partners, L.P. | 1.8% | ||||
| Farallon Capital Institutional Partners, L.P. | 2.5% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.6% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.3% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.4% | ||||
| Farallon Capital Offshore Investors II, L.P. | 4.0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.2% | ||||
| Farallon Capital F5 Master I, L.P. | 0.6% | ||||
| Farallon Partners, L.L.C. | 9.4% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.4% | ||||
| Farallon F5 (GP), L.L.C. | 0.6% | ||||
| Dapice Joshua J. | 10.0% | ||||
| Dreyfuss, Philip D. | 10.0% | ||||
| Dunn Hannah E. | 10.0% | ||||
| Fried, Richard B | 10.0% | ||||
| Gehani, Varun N. | 10.0% | ||||
| Giauque, Nicolas | 10.0% | ||||
| Kim, David T. | 10.0% | ||||
| Linn, Michael G. | 10.0% | ||||
| Luo Patrick (Cheng) | 10.0% | ||||
| Patel, Rajiv A. | 10.0% | ||||
| Roberts, Jr., Thomas G. | 10.0% | ||||
| Saito Edric C. | 10.0% | ||||
| Seybold, William | 10.0% | ||||
| Short Daniel S. | 10.0% | ||||
| Spokes, Andrew J. M. | 10.0% | ||||
| Warren, John R. | 10.0% | ||||
| Wehrly, Mark C. | 10.0% | ||||
|
Enanta Pharmaceuticals, Inc.
13G/A
Amendment 6
ENTA · 29251M106
|
9.9% |
2/11/2025
Event 12/31/2024
|
|||
| Farallon Capital Partners, L.P. | 1.9% | ||||
| Farallon Capital Institutional Partners, L.P. | 2.2% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.3% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.4% | ||||
| Farallon Capital Offshore Investors II, L.P. | 3.9% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.2% | ||||
| Farallon Capital F5 Master I, L.P. | 0.7% | ||||
| Farallon Partners, L.L.C. | 9.3% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.4% | ||||
| Farallon F5 (GP), L.L.C. | 0.7% | ||||
| Dapice Joshua J. | 9.9% | ||||
| Dreyfuss, Philip D. | 9.9% | ||||
| Dunn Hannah E. | 9.9% | ||||
| Fried, Richard B | 9.9% | ||||
| Gehani, Varun N. | 9.9% | ||||
| Giauque, Nicolas | 9.9% | ||||
| Kim, David T. | 9.9% | ||||
| Linn, Michael G. | 9.9% | ||||
| Luo Patrick (Cheng) | 9.9% | ||||
| Patel, Rajiv A. | 9.9% | ||||
| Roberts, Jr., Thomas G. | 9.9% | ||||
| Saito Edric C. | 9.9% | ||||
| Seybold, William | 9.9% | ||||
| Short Daniel S. | 9.9% | ||||
| Spokes, Andrew J. M. | 9.9% | ||||
| Warren, John R. | 9.9% | ||||
| Wehrly, Mark C. | 9.9% | ||||
|
AleAnna, Inc.
13G/A
Amendment 5
ANNA · 01444V103
|
2.6% |
2/10/2025
Event 12/31/2024
|
|||
| Farallon Capital Partners, L.P. | 0.4% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.1% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.1% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0.2% | ||||
| Farallon Capital Management, L.L.C. | 0.1% | ||||
| Farallon Partners, L.L.C. | 2.3% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.2% | ||||
| Dapice Joshua J. | 2.6% | ||||
| Dreyfuss, Philip D. | 2.6% | ||||
| Dunn Hannah E. | 2.6% | ||||
| Fried, Richard B | 2.6% | ||||
| Gehani, Varun N. | 2.6% | ||||
| Giauque, Nicolas | 2.6% | ||||
| Kim, David T. | 2.6% | ||||
| Linn, Michael G. | 2.6% | ||||
| Luo Patrick (Cheng) | 2.6% | ||||
| Patel, Rajiv A. | 2.6% | ||||
| Roberts, Jr., Thomas G. | 2.6% | ||||
| Saito Edric C. | 2.6% | ||||
| Seybold, William | 2.6% | ||||
| Short Daniel S. | 2.6% | ||||
| Spokes, Andrew J. M. | 2.6% | ||||
| Warren, John R. | 2.6% | ||||
| Wehrly, Mark C. | 2.6% | ||||
|
Forte Biosciences, Inc.
13G/A
Amendment 2
FBRX · 34962G109
|
3.4% |
2/10/2025
Event 12/31/2024
|
|||
| Farallon Capital Partners, L.P. | 0.6% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.8% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.3% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.3% | ||||
| Farallon Partners, L.L.C. | 3.1% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.3% | ||||
| Dapice Joshua J. | 3.4% | ||||
| Dreyfuss, Philip D. | 3.4% | ||||
| Dunn Hannah E. | 3.4% | ||||
| Fried, Richard B | 3.4% | ||||
| Gehani, Varun N. | 3.4% | ||||
| Giauque, Nicolas | 3.4% | ||||
| Kim, David T. | 3.4% | ||||
| Linn, Michael G. | 3.4% | ||||
| Luo Patrick (Cheng) | 3.4% | ||||
| Patel, Rajiv A. | 3.4% | ||||
| Roberts, Jr., Thomas G. | 3.4% | ||||
| Saito Edric C. | 3.4% | ||||
| Seybold, William | 3.4% | ||||
| Short Daniel S. | 3.4% | ||||
| Spokes, Andrew J. M. | 3.4% | ||||
| Warren, John R. | 3.4% | ||||
| Wehrly, Mark C. | 3.4% | ||||
|
Protagonist Therapeutics, Inc.
13G/A
Amendment 7
PTGX · 74366E102
|
10.0% |
2/10/2025
Event 12/31/2024
|
|||
| Farallon Capital Partners, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.5% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.0% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.2% | ||||
| Farallon Healthcare Partners Master, L.P. | 7.4% | ||||
| Farallon Partners, L.L.C. | 9.8% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.2% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 7.4% | ||||
| Dapice Joshua J. | 10.0% | ||||
| Dreyfuss, Philip D. | 10.0% | ||||
| Dunn Hannah E. | 10.0% | ||||
| Fried, Richard B | 10.0% | ||||
| Gehani, Varun N. | 10.0% | ||||
| Giauque, Nicolas | 10.0% | ||||
| Kim, David T. | 10.0% | ||||
| Linn, Michael G. | 10.0% | ||||
| Luo Patrick (Cheng) | 10.0% | ||||
| Patel, Rajiv A. | 10.0% | ||||
| Roberts, Jr., Thomas G. | 10.0% | ||||
| Saito Edric C. | 10.0% | ||||
| Seybold, William | 10.0% | ||||
| Short Daniel S. | 10.0% | ||||
| Spokes, Andrew J. M. | 10.0% | ||||
| Warren, John R. | 10.0% | ||||
| Wehrly, Mark C. | 10.0% | ||||
|
Beam Therapeutics Inc.
13G/A
Amendment 3
BEAM · 07373V105
|
9.9% |
2/5/2025
Event 12/31/2024
|
|||
| Farallon Capital Partners, L.P. | 0.7% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.8% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.2% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.7% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.4% | ||||
| Farallon Healthcare Partners Master, L.P. | 5.8% | ||||
| Farallon Partners, L.L.C. | 9.6% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.2% | ||||
| Farallon F5 (GP), L.L.C. | 0.4% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 5.8% | ||||
| Dapice Joshua J. | 9.9% | ||||
| Dreyfuss, Philip D. | 9.9% | ||||
| Dunn Hannah E. | 9.9% | ||||
| Fried, Richard B | 9.9% | ||||
| Gehani, Varun N. | 9.9% | ||||
| Giauque, Nicolas | 9.9% | ||||
| Kim, David T. | 9.9% | ||||
| Linn, Michael G. | 9.9% | ||||
| Luo Patrick (Cheng) | 9.9% | ||||
| Patel, Rajiv A. | 9.9% | ||||
| Roberts, Jr., Thomas G. | 9.9% | ||||
| Saito Edric C. | 9.9% | ||||
| Seybold, William | 9.9% | ||||
| Short Daniel S. | 9.9% | ||||
| Spokes, Andrew J. M. | 9.9% | ||||
| Warren, John R. | 9.9% | ||||
| Wehrly, Mark C. | 9.9% | ||||
|
The New York Times Company
13G/A
Amendment 1
NYT · 650111107
|
4.5% |
2/5/2025
Event 12/31/2024
|
|||
| Farallon Capital Partners, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.3% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.1% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||||
| Four Crossings Institutional Partners V, L.P. | 0% | ||||
| Farallon Capital Offshore Investors II, L.P. | 0.5% | ||||
| Farallon Capital (AM) Investors, L.P. | 0% | ||||
| Farallon Capital F5 Master I, L.P. | 0.1% | ||||
| Farallon Equity Partners Master, L.P. | 3.3% | ||||
| Farallon Partners, L.L.C. | 4.4% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||||
| Farallon F5 (GP), L.L.C. | 0.1% | ||||
| Farallon Equity Partners (GP), L.L.C. | 3.3% | ||||
| Dapice Joshua J. | 4.5% | ||||
| Dreyfuss, Philip D. | 4.5% | ||||
| Dunn Hannah E. | 4.5% | ||||
| Fried, Richard B | 4.5% | ||||
| Gehani, Varun N. | 4.5% | ||||
| Giauque, Nicolas | 4.5% | ||||
| Kim, David T. | 4.5% | ||||
| Linn, Michael G. | 4.5% | ||||
| Luo Patrick (Cheng) | 4.5% | ||||
| Patel, Rajiv A. | 4.5% | ||||
| Roberts, Jr., Thomas G. | 4.5% | ||||
| Saito Edric C. | 4.5% | ||||
| Seybold, William | 4.5% | ||||
| Short Daniel S. | 4.5% | ||||
| Spokes, Andrew J. M. | 4.5% | ||||
| Warren, John R. | 4.5% | ||||
| Wehrly, Mark C. | 4.5% | ||||
|
Elevation Oncology, Inc.
13G/A
Amendment 2
ELEV · 28623U101
|
6.0% |
2/5/2025
Event 12/31/2024
|
|||
| Farallon Capital Partners, L.P. | 1.2% | ||||
| Farallon Capital Institutional Partners, L.P. | 1.1% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.3% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.2% | ||||
| Farallon Capital Offshore Investors II, L.P. | 2.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.7% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Partners, L.L.C. | 5.3% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.2% | ||||
| Farallon F5 (GP), L.L.C. | 0.7% | ||||
| Dapice Joshua J. | 6.0% | ||||
| Dreyfuss, Philip D. | 6.0% | ||||
| Dunn Hannah E. | 6.0% | ||||
| Fried, Richard B | 6.0% | ||||
| Gehani, Varun N. | 6.0% | ||||
| Giauque, Nicolas | 6.0% | ||||
| Kim, David T. | 6.0% | ||||
| Linn, Michael G. | 6.0% | ||||
| Luo Patrick (Cheng) | 6.0% | ||||
| Patel, Rajiv A. | 6.0% | ||||
| Roberts, Jr., Thomas G. | 6.0% | ||||
| Saito Edric C. | 6.0% | ||||
| Seybold, William | 6.0% | ||||
| Short Daniel S. | 6.0% | ||||
| Spokes, Andrew J. M. | 6.0% | ||||
| Warren, John R. | 6.0% | ||||
| Wehrly, Mark C. | 6.0% | ||||
|
Lantheus Holdings, Inc.
13G/A
Amendment 1
CATX · 46489V104
|
7.6% |
2/5/2025
Event 12/31/2024
|
|||
| Farallon Capital Partners, L.P. | 0.6% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.6% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.1% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.1% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.3% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.2% | ||||
| Farallon Healthcare Partners Master, L.P. | 4.6% | ||||
| Farallon Partners, L.L.C. | 7.4% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | ||||
| Farallon F5 (GP), L.L.C. | 0.2% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 4.6% | ||||
| Dapice Joshua J. | 7.6% | ||||
| Dreyfuss, Philip D. | 7.6% | ||||
| Dunn Hannah E. | 7.6% | ||||
| Fried, Richard B | 7.6% | ||||
| Gehani, Varun N. | 7.6% | ||||
| Giauque, Nicolas | 7.6% | ||||
| Kim, David T. | 7.6% | ||||
| Linn, Michael G. | 7.6% | ||||
| Luo Patrick (Cheng) | 7.6% | ||||
| Patel, Rajiv A. | 7.6% | ||||
| Roberts, Jr., Thomas G. | 7.6% | ||||
| Saito Edric C. | 7.6% | ||||
| Seybold, William | 7.6% | ||||
| Short Daniel S. | 7.6% | ||||
| Spokes, Andrew J. M. | 7.6% | ||||
| Warren, John R. | 7.6% | ||||
| Wehrly, Mark C. | 7.6% | ||||
|
Agios Pharmaceuticals, Inc.
13G/A
Amendment 3
AGIO · 00847X104
|
9.9% |
2/4/2025
Event 12/31/2024
|
|||
| Farallon Capital Partners, L.P. | 0.7% | ||||
| Farallon Capital Institutional Partners, L.P. | 0.8% | ||||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | ||||
| Four Crossings Institutional Partners V, L.P. | 0.2% | ||||
| Farallon Capital Offshore Investors II, L.P. | 1.5% | ||||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||||
| Farallon Capital F5 Master I, L.P. | 0.4% | ||||
| Farallon Healthcare Partners Master, L.P. | 5.8% | ||||
| Farallon Partners, L.L.C. | 9.6% | ||||
| Farallon Institutional (GP) V, L.L.C. | 0.2% | ||||
| Farallon F5 (GP), L.L.C. | 0.4% | ||||
| Farallon Healthcare Partners (GP), L.L.C. | 5.8% | ||||
| Dapice Joshua J. | 9.9% | ||||
| Dreyfuss, Philip D. | 9.9% | ||||
| Dunn Hannah E. | 9.9% | ||||
| Fried, Richard B | 9.9% | ||||
| Gehani, Varun N. | 9.9% | ||||
| Giauque, Nicolas | 9.9% | ||||
| Kim, David T. | 9.9% | ||||
| Linn, Michael G. | 9.9% | ||||
| Luo Patrick (Cheng) | 9.9% | ||||
| Patel, Rajiv A. | 9.9% | ||||
| Roberts, Jr., Thomas G. | 9.9% | ||||
| Saito Edric C. | 9.9% | ||||
| Seybold, William | 9.9% | ||||
| Short Daniel S. | 9.9% | ||||
| Spokes, Andrew J. M. | 9.9% | ||||
| Warren, John R. | 9.9% | ||||
| Wehrly, Mark C. | 9.9% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.